Home
/
ARS Pharmaceuticals, Inc.
/
Financials
/
Quarterly
ARS Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that ARS Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$32.50M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$15.72M
Aug 13, 2025
Q1
2025
Mar 31, 2025
$7.97M
May 14, 2025
Q3
2025
Sep 30, 2024
$2.07M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$500.0K
Aug 13, 2025
Q1
2025
Mar 31, 2024
$0
May 14, 2025
Q3
2024
Sep 30, 2023
$0
Nov 13, 2024
Q2
2024
Jun 30, 2023
$10.0K
Aug 6, 2024
Q1
2024
Mar 31, 2023
$20.0K
May 9, 2024
Q3
2023
Sep 30, 2022
$189.0K
Nov 9, 2023
Q2
2023
Jun 30, 2022
$464.0K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$663.0K
May 15, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($51.15M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($44.88M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($33.94M)
May 14, 2025
Q3
2025
Sep 30, 2024
($19.13M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($12.52M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($10.29M)
May 14, 2025
Q3
2024
Sep 30, 2023
($14.87M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($17.37M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($14.96M)
May 9, 2024
Q3
2023
Sep 30, 2022
($6.58M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($6.42M)
Aug 10, 2023
Q2
2022
Mar 31, 2022
($24.63M)
Aug 11, 2022
Q1
2023
Mar 31, 2022
($7.25M)
May 15, 2023
Q3
2022
Sep 30, 2021
($22.66M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($24.50M)
Aug 11, 2022
Q2
2022
Mar 31, 2021
($18.87M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($18.87M)
May 12, 2022
Q3
2021
Sep 30, 2020
($8.12M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($6.47M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($5.28M)
May 13, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($53.19M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($47.61M)
Aug 13, 2025
Q1
2025
Mar 31, 2025
($37.18M)
May 14, 2025
Q3
2025
Sep 30, 2024
($21.75M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($15.34M)
Aug 13, 2025
Q1
2025
Mar 31, 2024
($13.19M)
May 14, 2025
Q3
2024
Sep 30, 2023
($17.98M)
Nov 13, 2024
Q2
2024
Jun 30, 2023
($20.60M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($18.71M)
May 9, 2024
Q3
2023
Sep 30, 2022
($6.63M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($6.34M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($7.10M)
May 15, 2023
Q3
2022
Sep 30, 2021
($22.68M)
Nov 2, 2022
Q2
2022
Jun 30, 2021
($24.51M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($18.89M)
May 12, 2022
Q3
2021
Sep 30, 2020
($8.11M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($6.46M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($5.24M)
May 13, 2021